Drug Type Small molecule drug |
Synonyms 希美替尼, SOMCL 15 290, SOMCL-15-290 + [1] |
Target |
Mechanism FGFRs antagonists(Fibroblast growth factor receptors antagonists), M-CSF inhibitors(Macrophage Colony Stimulating Factor 1 inhibitors), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Esophageal Squamous Cell Carcinoma | Phase 2 | CN | 26 Feb 2024 | |
Esophageal Squamous Cell Carcinoma | Phase 2 | CN | 26 Feb 2024 | |
HR-positive/HER2-low Solid Tumors | Phase 2 | CN | 30 Jan 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 07 Dec 2023 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 07 Dec 2023 | |
Cholangiocarcinoma | Phase 2 | CN | - | |
squamous cell lung carcinoma | Phase 2 | CN | - | |
Stomach Cancer | Phase 2 | CN | - | |
Breast Cancer | Phase 1 | CN | - | |
Transitional Cell Carcinoma | Phase 1 | CN | - |
Phase 1 | Advanced Malignant Solid Neoplasm FGF3 | FGF4 | FGF19 | 98 | rpmskivccr(sljndxjhts) = MTD was not achieved gwphijqkzo (iuciwuemlh ) | Positive | 24 May 2024 | ||
Simmitinib 6 mg 3 weeks on 1 week off |